Recently developed FAP-targeting bi-specific antibody (colorectal and pancreatic cancer)100, antibody-drug conjugate (ADC) (pancreatic, ovarian, and lung cancer)101, potently increased T cell Infiltration and control tumor growth in pre-clinical models. Here, FAP is linked to familial pancreatic carcinoma.